Vahé Barsegian1, Stefan P Müller2, Daniel Möckel1, Peter A Horn3, Andreas Bockisch2, Monika Lindemann4. 1. Institute of Nuclear Medicine, Helios Kliniken, Wismarsche Straße 393-397, 19049, Schwerin, Germany. 2. Department of Nuclear Medicine, University Hospital Essen, Hufelandstraße 55, 45147, Essen, Germany. 3. Institute for Transfusion Medicine, University Hospital Essen, Virchowstraße 179, 45147, Essen, Germany. 4. Institute for Transfusion Medicine, University Hospital Essen, Virchowstraße 179, 45147, Essen, Germany. monika.lindemann@uk-essen.de.
Abstract
PURPOSE: Therapy with the alpha-emitter radium-223 chloride (223Ra) is an innovative therapeutic option in patients with metastasized, castration-resistant prostate cancer. However, radiotherapy can lead to hematopoietic toxicity. The aim of this study was to determine if 223Ra therapy induces an impairment of cellular antimicrobial immune responses. METHODS: In 11 patients receiving 223Ra treatment, lymphocyte proliferation and the production of pro- and anti-inflammatory cytokines (interferon-γ and interleukin-10) were determined, using lymphocyte transformation testing and ELISpot, respectively. Lymphocyte function after stimulation with mitogens and microbial antigens was assessed prior to therapy and at day 1, 7 and 28 after therapy. RESULTS: Lymphocyte proliferation and the production of interferon-γ and interleukin-10 towards mitogens and antigens remained unchanged after therapy. Consistent with these in vitro data, we did not observe infectious complications after treatment. CONCLUSIONS: The results argue against an impairment of lymphocyte function after 223Ra therapy. Thus, immune responses against pathogens should remain unaffected.
PURPOSE: Therapy with the alpha-emitter radium-223 chloride (223Ra) is an innovative therapeutic option in patients with metastasized, castration-resistant prostate cancer. However, radiotherapy can lead to hematopoietic toxicity. The aim of this study was to determine if 223Ra therapy induces an impairment of cellular antimicrobial immune responses. METHODS: In 11 patients receiving 223Ra treatment, lymphocyte proliferation and the production of pro- and anti-inflammatory cytokines (interferon-γ and interleukin-10) were determined, using lymphocyte transformation testing and ELISpot, respectively. Lymphocyte function after stimulation with mitogens and microbial antigens was assessed prior to therapy and at day 1, 7 and 28 after therapy. RESULTS: Lymphocyte proliferation and the production of interferon-γ and interleukin-10 towards mitogens and antigens remained unchanged after therapy. Consistent with these in vitro data, we did not observe infectious complications after treatment. CONCLUSIONS: The results argue against an impairment of lymphocyte function after 223Ra therapy. Thus, immune responses against pathogens should remain unaffected.
Authors: John L Humm; Oliver Sartor; Chris Parker; Oyvind S Bruland; Roger Macklis Journal: Int J Radiat Oncol Biol Phys Date: 2015-04-01 Impact factor: 7.038
Authors: Vahé Barsegian; Christian Hueben; Stefan P Mueller; Thorsten D Poeppel; Peter A Horn; Andreas Bockisch; Monika Lindemann Journal: Cancer Immunol Immunother Date: 2015-03-31 Impact factor: 6.968
Authors: Monika Lindemann; Oliver Witzke; Toni Winterhagen; Birgit Ross; Ernst Kreuzfelder; Walter Reinhardt; Michael Roggendorf; Klaus Mann; Thomas Philipp; Hans Grosse-Wilde Journal: AIDS Date: 2004-10-21 Impact factor: 4.177
Authors: Catherine H Marshall; Wei Fu; Hao Wang; Jong Chul Park; Theodore L DeWeese; Phuoc T Tran; Daniel Y Song; Serina King; Michaella Afful; Julia Hurrelbrink; Charlotte Manogue; Patrick Cotogno; Nancy P Moldawer; Pedro C Barata; Charles G Drake; Edwin M Posadas; Andrew J Armstrong; Oliver Sartor; Emmanuel S Antonarakis Journal: Clin Cancer Res Date: 2021-01-15 Impact factor: 13.801